Medical Advocates
Tipranavir (Aptivus)
Pediatric Data

 New and Noteworthy
FDA Updates
 Journal Data






 		  
Tipranavir Main Page  Main New/Newsworthy 

Home Page

      
Last Update:  July 30, 2015 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
September 2013
 
FDA/EU Updates
     

FDA Updates
       
     Label Updates
 
  PDF DOCUMENT
 New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information
on coadministration with midazolam
US FDA  June 23, 2008
 Document

Journal Citations
       
 
Efficacy and Safety of Tipranavir Co-Administered with Ritonavir in HIV-1-Infected Children and Adolescents: 5 Years of Experience
 Salazar JC, Cahn P, Negra MD,  et al
Pediatr Infect Dis J. 2013 Aug 29
 Abstract

A 12-year-old Boy with Multidrug-resistant Human Immunodeficiency Virus Type 1 Successfully Treated with
HAART Including Ritonavir-boosted Tipranavir Oral Solution and Enfuvirtide.
 Feiterna-Sperling C, Walter H, Wahn V, Kleinkauf N.
Eur J Med Res. 2009 Jan 28;14(1):44-6.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
 Tipranavir: a new protease inhibitor for the pediatric population.
 Courter JD, Girotto JE, Salazar JC.
Expert Rev Anti Infect Ther. 2008 Dec;6(6):797-803.
 Abstract

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children
and adolescents.
Salazar JC, Cahn P, Yogev R, et al
AIDS. 2008 Sep 12;22(14):1789-98.
 Abstract

Tipranavir Main Page  Main New/Newsworthy 

Home Page

      

Tipranavir Pediatric Data